普鲁兰二甲交联双作用粘合剂具有较高的对肺组织的粘合力,并具有pH响应药物释放能力
Ke Zhang1, Hui Huang2, Yilin Zhao1
1School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China.
Carbohydrate polymers
|November 20, 2024
概括
研究人员从鱼皮凝和pullulan dialdehyde中开发了一种新型肺粘合剂,用于密封空气泄漏和输送化疗药物. 这种双重作用的粘合剂在减少肺癌患者手术后并发症方面表现有前途.
科学领域:
- 生物材料科学 生物材料科学
- 手术创新 在外科创新.
- 药物输送系统 药物输送系统
背景情况:
- 胸腔镜肺癌手术面临着持续的空气泄漏和癌症复发等挑战.
- 现有的治疗方法往往缺乏向药物输送和有效的密封能力.
研究的目的:
- 为肺癌手术开发一种现场,pH响应的粘合剂.
- 创建一个双重作用的系统来封闭空气泄漏和释放抗癌药物.
主要方法:
- 使用防水修饰的冷水鱼皮凝 (hm-CFG) 和pullulan dialdehyde (PDA) 制备一个肺粘合剂.
- 添加基二化物修饰的多克索鲁比辛 (SDH-DOX) 以释放适应pH的药物.
- 优化粘合剂配方 (9C10-CFG/PDA) 并评估其机械性能和密封效果在老鼠肺胸模型中.
主要成果:
- 最佳的9C10-CFG/PDA粘合剂表现出极好的凝聚力,机械灵活性 (应变>170%) 和界面粘合力.
- 这种粘合剂的破裂强度几乎是商业纤维素密封剂的六倍.
- 在体内测试显示有利的伤口密封性质和恢复了老鼠的行为.
- 与未经修改的多克索鲁比辛相比,SDH-DOX@Adhesive配方提供了更渐进的,对pH值敏感的药物释放.
结论:
- 开发的双重作用粘合剂有效地封闭了肺部空气泄漏,并以响应pH的方式提供抗癌药物.
- 这种创新的生物材料具有减轻术后并发症和改善肺癌治疗结果的潜力.
相关概念视频
01:30Adrenergic Agonists: Direct-Acting Agents
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
01:22Drug Delivery: Miscellaneous Routes
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...